Uzedy (Risperidone SC Monthly) is filed as Long-Acting Injectable Antipsychotic. The sections below restate public label fields stored for this profile.
1 INDICATIONS AND USAGE UZEDY is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults. ( 1.1 ) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. ( 1.2 ) 1.1 Schizophrenia UZEDY is indicated for the treatment of schizophrenia in adults . 1.2 Bipolar Disorder UZEDY is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder in adults.
12.1 Mechanism of Action The mechanism of action of risperidone, for the listed indications, is unclear. The drug’s therapeutic activity could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone (paliperidone) [see Clinical Pharmacology ( 12.3 )] . Antagonism at receptors other than D 2 and 5HT 2 may explain some of the other effects of risperidone.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for the treatment of patients with dementia-related psychosis and has not been studied in this patient population [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for use in patients with dementia-related psychosis. ( 5.1 )
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for the treatment of patients with dementia-related psychosis and has not been studied in this patient population [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for use in patients with dementia-related psychosis. ( 5.1 )
4 CONTRAINDICATIONS UZEDY is contraindicated in patients with a known hypersensitivity to risperidone, its metabolite, paliperidone, or to any of its components. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone or paliperidone. Known hypersensitivity to risperidone, paliperidone, or to any of the components in UZEDY. ( 4 )
Patients (13%)
The following are discussed in more detail in other sections of the labeling: Increased mortality in elderly patients with dementia-related psychosis [see Boxed Warning and Warnings and Precautions ( 5.1 )] Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis [see Warnings and Precautions ( 5.2 )] Neuroleptic malignant syndrome [see Warnings and Precautions ( 5.3 )] Tardive dyskinesia [see Warnings and Precautions ( 5.4 )] Metabolic changes [see Warnings and Precautions ( 5.5 )] Hyperprolactinemia [see Warnings and Precautions ( 5.6 )] Orthostatic hypotension and syncope [see Warnings and Precautions ( 5.7 )] Falls [see Warnings and Precautions ( 5.8 )] Leukopenia, neutropenia and agranulocytosis [see Warnings and Precautions ( 5.9 )] Potential for cognitive and motor impairment [see Warnings and Precautions ( 5.10 )] Seizures [see Warnings and Precautions ( 5.11 )] Dysphagia [see Warnings and Precautions ( 5.12 )] Priapism [see Warnings and Precautions ( 5.13 )] Body temperature regulation [see Warnings and Precautions ( 5.14 )]
2 DOSAGE AND ADMINISTRATION Establish tolerability with oral risperidone prior to initiating UZEDY. ( 2.1 ) Administer UZEDY by subcutaneous injection in the abdomen or upper arm by a healthcare professional. Do not administer by any other route. ( 2.1 ) See Full Prescribing Information for important preparation and administration information. ( 2.7 ) Schizophrenia Initiate UZEDY at the clinically appropriate dose using the following table. ( 2.2 ) Comparable Daily Oral Risperidone Therapy UZEDY Dosage Once Monthly UZEDY Dosage Once Every 2 Months 2 mg 50 mg 100 mg 3 mg 75 mg 150 mg 4 mg 100 mg 200 mg 5 mg 125 mg 250 mg Bipolar I disorder Following establishment of tolerability with oral risperidone, initiate UZEDY at the clinically appropriate dose using the following table. ( 2.3 ) Comparable Daily Oral Risperidone Therapy UZEDY Dosage Once Monthly 2 mg 50 mg 3 mg 75 mg 4 mg 100 mg For patients currently receiving risperidone long acting intramuscular injectable given once every 2 weeks, switch to UZEDY as a once monthly injection, starting at least 5 weeks after the last dose of risperidone long acting injectable given once every 2 weeks. ( 2.3 ) Switch to UZEDY at the clinically appropriate dose using the following table. ( 2.3 ). Another Risperidone Long-Acting Intramuscular Injection Given Once Every 2 Weeks UZEDY Dosage Once Monthly 25 mg 50 mg 37.5 mg 75 mg 50 mg 100 mg 2.1 General Administration Information For patients who have never taken risperidone, establish tolerability with oral risperidone prior to initiating UZEDY. UZEDY must be administered by a healthcare professional as an abdominal or upper arm subcutaneous injection. Do not administer UZEDY by any other route. For detailed preparation and administration instructions, see Dosage and Administration ( 2.7 ) . 2.2 Dosage Recommendations for the Treatment of Schizophrenia To start UZEDY for the treatment of schizophrenia, switch from oral daily risperidone. Initiate UZEDY, as either a once monthly injection or a once every 2 month injection, the day after the last dose of oral therapy. See Table 1 to determine how to switch from oral risperidone to UZEDY once monthly (50 mg, 75 mg, 100 mg, or 125 mg) or once every 2 months (100 mg, 150 mg, 200 mg, or 250 mg) given via abdominal or upper arm subcutaneous injection. Neither a loading dose nor supplemental oral risperidone doses are recommended when switching. Table 1: Dosage Recommendations for Switching from Daily Oral Risperidone to UZEDY Given Once Monthly or Once Every 2 Months Comparable Daily Oral Risperidone Therapy UZEDY Dosage Once Monthly UZEDY Dosage Once Every 2 Months 2 mg 50 mg 100 mg 3 mg 75 mg 150 mg 4 mg 100 mg 200 mg 5 mg 125 mg 250 mg Patients can switch between doses of UZEDY once monthly and once every 2 months by administering the first dose of the new dosing regimen on the next scheduled date of administration in the original dosing regimen. Revise the dose administration schedule to reflect the change. 2.3 Dosage Recommendations for Maintenance Treatment of Bipolar I Disorder Following establishment of tolerability with oral risperidone, start UZEDY as a once monthly injection for monotherapy or adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder, according to the dosage recommendations in Table 2 . UZEDY once every 2 months injection is not recommended for the maintenance treatment of bipolar I disorder. Table 2: Dosage Recommendations for Switching from Daily Oral Risperidone to UZEDY Given Once Monthly Comparable Daily Oral Risperidone Therapy UZEDY Dosage Once Monthly 2 mg 50 mg 3 mg 75 mg 4 mg 100 mg For patients currently receiving risperidone long acting intramuscular injectable given once every 2 weeks, switch to UZEDY as a once monthly subcutaneous injection, starting at least 5 weeks after the last dose of risperidone long acting intramuscular injectable given once every 2 weeks. Refer to Table 3 to determine how to switch from risperidone long acting injectable given once every 2 weeks to UZEDY once monthly (50 mg, 75 mg, 100 mg) subcutaneous injection given via abdominal or upper arm. Neither a loading dose nor supplemental oral risperidone doses are recommended when initiating UZEDY. Table 3: Dosage Recommendations for Switching From Another Risperidone Long-Acting Intramuscular Injection Given Once Every 2 Weeks To UZEDY Given Once Monthly Another Risperidone Long-Acting Intramuscular Injection Given Once Every 2 Weeks UZEDY Dosage Once Monthly 25 mg 50 mg 37.5 mg 75 mg 50 mg 100 mg 2.4 Missed Doses When a dose of UZEDY is missed, administer the next UZEDY injection as soon as possible. Do not administer more frequently than recommended. 2.5 Dosage Modifications in Patients with Renal Impairment or Hepatic Impairment Prior to initiating UZEDY in patients with renal or hepatic impairment, titrate with oral risperidone to at least 2 mg once daily. Following oral titration, and based on clinical response and tolerability, the recommended dosage of UZEDY is 50 mg once monthly [see Use in Specific Populations ( 8.6 , 8.7 ) and Clinical Pharmacology ( 12.3 )]. 2.6 Dosage Modifications for Concomitant Use with Strong CYP2D6 Inhibitors and Strong CYP3A4 Inducers Concomitant Use with Strong CYP2D6 Inhibitors When initiation of fluoxetine or paroxetine is considered, place patients on a lower dose of UZEDY prior to the planned start of fluoxetine or paroxetine therapy to adjust for the expected increase in plasma concentrations of risperidone. When fluoxetine or paroxetine is initiated in patients receiving the recommended dose of 50 mg once monthly or 100 mg once every 2 months of UZEDY, continue treatment with these doses unless clinical judgment necessitates interruption of UZEDY [see Drug Interactions ( 7.1 )] . Concomitant Use with Strong CYP3A4 Inducers At the initiation of therapy with strong CYP3A4 inducers (such as carbamazepine), patients should be closely monitored during the first 4 to 8 weeks since the dose of UZEDY may need to be adjusted. A dose increase, or additional oral risperidone, may be considered. On discontinuation of a strong CYP3A4 inducer, re-evaluated the dosage of UZEDY or any additional oral risperidone therapy and, if necessary, decrease to adjust for the expected increase in plasma concentration of risperidone. On discontinuation of a strong CYP3A4 inducer in a patient treated with UZEDY 50 mg once monthly or 100 mg once every 2 months, continue treatment with these doses unless clinical judgment necessitates interruption of UZEDY [see Drug Interactions ( 7.1 )] . 2.7 Preparation and Administration Instructions Read the instructions for preparation and administration below before administering UZEDY. For subcutaneous injection only. Do not inject by any other route. To be administered by a healthcare professional only. Allow UZEDY to come to room temperature for at least 30 minutes prior to administration. As a universal precaution, always wear gloves. STEP 1 Check to make sure UZEDY kit contains: One sterile single-dose, prefilled glass syringe One sterile 21G x 5/8” needle Do not substitute any components of the kit for administration. STEP 2 Remove the kit from refrigerated storage and allow the package to sit at room temperature (20°C to 25°C [68°F to 77°F]) for at least 30 minutes. Note: UZEDY is a solid at refrigerated temperatures and must reach room temperature prior to administration. Do not warm any other way and keep protected from light. STEP 3 Check that the drug in the syringe is white to off-white, opaque in color, and free from non-white particulate matter. Check that the pouch label states the needle size is 21G x 5/8”. Do not use if any component of the kit is damaged or if the expiration date has passed. STEP 4 Expose the safety needle hub by peeling back the paper tab of the needle pouch. Set aside for use in Step 7. STEP 5 IMPORTANT: This step must be performed to ensure complete dosing. UZEDY is viscous and…
7 DRUG INTERACTIONS The interactions of UZEDY with co-administration of other drugs have not been studied. The drug interaction data provided in this section is based on studies with oral risperidone. Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): Increase risperidone plasma concentration. ( 2.6 , 7.1 ) Strong CYP3A4 inducers (e.g., carbamazepine): Decrease plasma concentrations of risperidone. ( 2.6 , 7.1 ) 7.1 Drugs Having Clinically Important Interactions with UZEDY Table 13 includes clinically significant drug interactions with UZEDY. Table 13: Clinically Important Drug Interactions with UZEDY Strong CYP2D6 Inhibitors Clinical Impact: Concomitant use of UZEDY with strong CYP2D6 inhibitors may increase the plasma exposure of risperidone and lower the plasma exposure of a major active metabolite, 9-hydroxyrisperidone [see Clinical Pharmacology ( 12.3 )] . Intervention: When initiation of strong CYP2D6 inhibitors is considered, patients may be placed on the lowest dose (50 mg once monthly or 100 mg once every 2 months) of UZEDY prior to the planned start of strong CYP2D6 inhibitors to adjust for the expected increase in plasma concentrations of risperidone. When strong CYP2D6 inhibitors are initiated in patients receiving UZEDY 50 mg once monthly or 100 mg once every 2 months, it is recommended to continue treatment with the same dose unless clinical judgment necessitates interruption of UZEDY treatment. The effects of discontinuation of strong CYP2D6 inhibitors on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied [see Clinical Pharmacology ( 12.3 )] . Strong CYP3A4 Inducers Clinical Impact: Concomitant use of UZEDY and a strong CYP3A4 inducer may cause decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone which could lead to decreased efficacy of UZEDY [see Clinical Pharmacology ( 12.3 )] . Intervention: Changes in efficacy and safety should be carefully monitored with any dose adjustment of UZEDY. At the initiation of therapy with a strong CYP3A4 inducer, patients should be closely monitored during the first 4 to 8 weeks. In patients receiving UZEDY at a specific dose, consider increasing the dose to the next highest dose. In patients receiving UZEDY 125 mg once monthly or 250 mg once every 2 months, additional oral risperidone therapy may need to be considered. On discontinuation of a strong CYP3A4 inducer, the dosage of UZEDY or any additional oral risperidone therapy should be reevaluated and, if necessary, decreased to adjust for the expected increase in plasma concentration of risperidone and 9-hydroxyrisperidone. For patients treated with UZEDY 50 mg once monthly or UZEDY 100 mg once every 2 months discontinuing from a strong CYP3A4 inducer, it is recommended to continue treatment with the same dose unless clinical judgment necessitates interruption of UZEDY treatment [see Dosage and Administration ( 2.6 )] . Centrally-Acting Drugs and Alcohol Clinical Impact: Due to additive pharmacologic effects, the concomitant use of centrally-acting drugs, including alcohol, may increase nervous system disorders. Intervention: Caution should be used when UZEDY is administered in combination with other centrally-acting drugs or alcohol. Hypotensive Agents Clinical Impact: Because of its potential for inducing hypotension, UZEDY may enhance the hypotensive effects of other therapeutic agents with this potential. Intervention: Caution should be used when UZEDY is administered with other therapeutic effects of other therapeutic agents with this potential. Dopamine Agonists Clinical Impact: Agents with central antidopaminergic activity such as UZEDY may antagonize the pharmacologic effects of dopamine agonists. Intervention: Caution should be used when UZEDY is administered in combination with levodopa and dopamine agonists. Methylphenidate Clinical Impact: Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS) [see Adverse Reactions ( 6.2 )] . Intervention: Monitor for symptoms of EPS with concomitant use of UZEDY and methylphenidate. 7.2 Drugs Having No Clinically Important Interactions with UZEDY Based on pharmacokinetic studies with oral risperidone, no dosage adjustment of UZEDY is required when administered concomitantly with amitriptyline, cimetidine, ranitidine, clozapine, topiramate, and moderate CYP3A4 inhibitors (erythromycin). Additionally, no dosage adjustment is necessary for lithium, valproate, topiramate, digoxin, and CYP2D6 substrates (donepezil and galantamine) when co-administered with UZEDY [see Clinical Pharmacology ( 12.3 )] .
According to its FDA label, Uzedy (Risperidone SC Monthly) is approved for: 1 INDICATIONS AND USAGE UZEDY is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults. ( 1.1 ) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. ( 1.2 ) 1.1 Schizophrenia UZE… For medical advice, please talk to your prescriber or pharmacist.
Uzedy (Risperidone SC Monthly) belongs to the Long-Acting Injectable Antipsychotic class of medications.
The FDA label lists Uzedy (Risperidone SC Monthly) as: 3 DOSAGE FORMS AND STRENGTHS Extended-release injectable suspension: sterile, white to off-white opaque viscous suspension available in the following strengths of risperidone: 50 mg/0.14 mL, 75 mg/0.21 mL, 100 mg/0.28 mL, 125 mg/0.35 mL, 150 mg/0.42 mL, 200 mg/0.56 mL, and 250 mg/0.7 mL. Extended-release injectable suspension, in the strengths of risperidone: 50 mg/0.14 mL, 75 mg/0.21 mL, 100 mg/0.28 mL, 125 mg/0.35 mL, 150 mg/0.42 mL, 200 mg/0.56 mL, and 250 mg/0.7 mL single-dose prefilled syringes. ( 3 ); subcutaneous route. Available strengths and packaging vary by manufacturer.
Yes. The FDA label for Uzedy (Risperidone SC Monthly) carries a Boxed Warning. Excerpt: "WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.
Public CMS NADAC pricing for Uzedy (Risperidone SC Monthly) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Uzedy (Risperidone SC Monthly) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Uzedy (Risperidone SC Monthly) as 2023-04-28.
The FDA label lists Teva Pharmaceuticals USA, Inc. as a labeler/manufacturer of Uzedy (Risperidone SC Monthly). Multiple firms may market generics of the same molecule.
The FDA label states: "How Supplied UZEDY (risperidone) extended-release injectable suspension, for subcutaneous use, is a sterile, preservative free, white to off-white opaque viscous suspension. UZEDY is supplied in single-dose kits as follo…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…